“…OMS could develop in the course of metabolic, toxic, or structural impairment of the central nervous system. [ 1 – 3 , 6 , 16 , 17 ] In both paraneoplastic opsoclonus-myoclonus syndrome (P-OMS) and idiopathic opsoclonus-myoclonus syndrome (I-OMS) humoral and cell-mediated immune mechanisms are involved, with the presumed dominant role of antibodies. [ 5 , 6 , 10 ] In some patients with P-OMS, a variety of onconeuronal antibodies are found (anti-Hu, anti-Yo, anti-Ri, anti-CRMP-5/CV2, anti-Ma1, anti-Ma2, anti-Tr, anti-Zic-4, anti-amphiphysin), although the majority of patients are seronegative (1, 3, 4, 5, 6, 18).…”